Stephen Ray Mitchell is Director at Vanda Pharmaceuticals Inc. (VNDA). They have made 6 open-market trades across 1 company since 2021, most recently 2026-06-04.
CIK 0001802653
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| VNDA | 112,846 | $456K |
Shares reported on the most recent Form 4, priced at the 2026-06-08 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VNDA | SELL | 2025-06-13 | 2025-06-16 | $4.59 | $32K | +5.5% | +6.2% | -3.3% |
| VNDA | SELL | 2024-11-14 | 2024-11-18 | $5.17 | $26K | +4.5% | -7.7% | -9.5% |
| VNDA | SELL | 2023-08-10 | 2023-08-11 | $6.05 | $39K | -2.2% | -22.1% | -43.9% |
| VNDA | SELL | 2022-06-13 | 2022-06-14 | $9.48 | $26K | +13.7% | +20.4% | +9.0% |
| VNDA | SELL | 2021-09-09 | 2021-09-13 | $16.74 | $640K | +4.3% | +9.3% | -3.9% |
| VNDA | SELL | 2021-06-15 | 2021-06-17 | $19.42 | $194K | +5.4% | -3.6% | -15.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.